Botulinum toxin type A complex [Nabota]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Botulinum toxin type A complex
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials
for the management of focal spasticity of the lower limbs associated with stroke in adults who:
have a score of 3 or more on the Modified Ashworth Scale at the target muscle intended for botulinum toxin A treatment;
do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle; and
are concurrently receiving physiotherapy.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
Funding status
[R] Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2023.
[R] Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials are recommended for inclusion on the MAF for the abovementioned indication from 1 November 2025.
[NR] MAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
The Ministry of Health’s Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials
for the management of focal spasticity of the upper limbs associated with stroke in adults who:
have a score of 2 or more on the Modified Ashworth Scale at the target muscle intended for botulinum toxin A treatment;
do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle; and
are concurrently receiving physiotherapy.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
Funding status
[R] Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 2 September 2019.
[R] Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials are recommended for inclusion on the MAF for the abovementioned indication from 1 November 2025.
[NR] MAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
16/09/2025 Botulinum toxin A for treating blepharospasm or hemifacial spasm (opens in new tab)
The Ministry of Health’s Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials
for treating adults with blepharospasm or hemifacial spasm.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
Funding status
[R] Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 2 September 2019.
[R] Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials are recommended for inclusion on the MAF for the abovementioned indications from 1 November 2025.
[NR] MAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
16/09/2025 Botulinum toxin A for treating cervical dystonia (opens in new tab)
The Ministry of Health’s Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials
for treating adults with cervical dystonia.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
Funding status
[R] Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 2 September 2019.
[R] Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials are recommended for inclusion on the MAF for the abovementioned indication from 1 November 2025.
[NR] MAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
The Ministry of Health’s Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials
for treating children, aged 2 years or older, with focal spasticity of the upper or lower limbs (including dynamic equinus foot deformity) due to cerebral palsy, and who:
do not have significant joint contractures, i.e. the affected joint is not permanently fixed in position due to shortening of the target muscle; and
are concurrently receiving ongoing supportive therapy, e.g. physiotherapy or occupational therapy.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
Funding status
[R] Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 2 September 2019.
[R] Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials are recommended for inclusion on the MAF for the abovementioned indication from 1 November 2025.
[NR] MAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab). The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information. |
Intramuscular
* Clinical information is available for this product.